unPAUSED with Dr. Mary Claire Haver GLP-1s and Midlife Metabolism: Dr. Rocio Salas-Whalen Breaks Down the Science of Weight Loss and Menopause: Part 1
32 snips
Nov 11, 2025 
Dr. Rocio Salas-Whalen, a triple board-certified internist and founder of New York Endocrinology, joins the conversation to discuss GLP-1 medications and their impact on midlife women. She explains how these drugs redefine obesity treatment as a chronic condition influenced by hormones and metabolism. The discussion dives into why estrogen decline leads to weight gain and abdominal fat, how GLP-1s can help, and the significance of preserving muscle mass during weight loss. Dr. Salas-Whalen also introduces her GPS protocol, combining GLP-1s with protein and strength training.
AI Snips
Chapters
Books
Transcript
Episode notes
From Diabetes Drug To Cultural Phenomenon
- GLP-1s originated as diabetes drugs with decades of safety data, then expanded to obesity treatment.
- Public perception shifted rapidly once weight-loss effects became visible in culture.
How GLP-1s Work And Reframe Obesity
- GLP-1s mimic a gut hormone that increases fullness, slows stomach emptying, and improves insulin handling.
- They shift obesity treatment from willpower to a biologically driven medical approach.
Offer GLP-1s Sooner When Biology Prevails
- Consider GLP-1s earlier for patients who have already tried diet and exercise without lasting results.
- Don't force patients to 'earn' medications after exhausting other options when biology drives weight.
